Skip to main content

Crizotinib Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Sep 21, 2022.


Commonly reported side effects of crizotinib include: increased serum alanine aminotransferase. Continue reading for a comprehensive list of adverse effects.

Applies to crizotinib: oral capsules.

Side effects include:

ALK-positive metastatic NSCLC (≥25%): Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated aminotransferase concentrations, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.

ALCL (≥35%): Diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, pyrexia, abdominal pain, cough, pruritus.

Grade 3 or 4 laboratory abnormalities (≥15%): Neutropenia, lymphopenia, thrombocytopenia.

For Healthcare Professionals

Applies to crizotinib: oral capsule.


Very common (10% or more): Vision disorders (e.g., diplopia, photophobia, photopsia, reduced visual acuity, blurred vision, vitreous floaters, visual impairment) (71%), ocular hypotension (19%)

Uncommon (0.1% to 1%): Severe vision loss[Ref]


Very common (10% or more): Bradycardia (19%)

Common (1% to 10%): QT interval prolongation, cardiac failure (e.g., cardiac failure, cardiac failure congestive, ejection fraction decreased, left ventricular failure, pulmonary edema), syncope[Ref]


Very common (10% or more): ALT elevation (79%), AST elevation (66%), increased alkaline phosphatase (19%)

Common (1% to 10%): Hepatic failure, increased gamma-glutamyl transferase[Ref]


Very common (10% or more): Neutropenia (22%), lymphopenia (18%), leukopenia (15%), anemia (15%)

Common (1% to 10%): Febrile neutropenia[Ref]


Very common (10% or more): Upper respiratory infection (e.g., nasopharyngitis, pharyngitis, rhinitis, upper respiratory tract infection) (32%)

Common (1% to 10%): Pulmonary embolism, interstitial lung disease[Ref]


Very common (10% or more): Diarrhea (61%), nausea (57%), vomiting (46%), constipation (43%), abdominal pain (26%), dyspepsia (14%), dysphagia (10%)

Common (1% to 10%): Esophagitis[Ref]


Very common (10% or more): Rash (13%)[Ref]


The most common adverse reactions (25% or more) are vision disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.[Ref]


Very common (10% or more): Hypophosphatemia (up to 32%), decreased appetite (27%), hypokalemia (18%), decreased weight (10%), hypernatremia (19%), hyponatremia (12%), hyperuricemia (12%)

Common (1% to 10%): Decreased blood testosterone (e.g., blood testosterone decreased, hypogonadism, secondary hypogonadism)

Uncommon (0.1% to 1%): Increased weight[Ref]

Nervous system

Very common (10% or more): Dysgeusia (26%), dizziness (e.g., balance disorder, dizziness, dizziness postural, presyncope) (26%), neuropathy (e.g., burning sensation, dysesthesia, formication, gait disturbance, hyperesthesia, hypoesthesia, hypotonia, motor dysfunction, muscle atrophy, muscular weakness, neuralgia, neuritis, neuropathy peripheral, neurotoxicity, paresthesia, peripheral motor neuropathy, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, peroneal nerve palsy, polyneuropathy, sensory disturbance, skin burning sensation) (25%)[Ref]


swelling, localized edema, peripheral edema, periorbital edema (49%), fatigue (30%), pyrexia (19%)[Ref]


Common (1% to 10%): Renal cyst (e.g., renal abscess, renal cyst, renal cyst hemorrhage, renal cyst infection), acute renal injury[Ref]


Very common (10% or more): Pain in extremity (16%)

Common (1% to 10%): Muscle spasm, muscular weakness[Ref]

Frequently asked questions


1. "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group (2011):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.